Citations (82)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Robby Barnestein, Loïck Galland, Laura Kalfeist, François Ghiringhelli, Sylvain Ladoire & Emeric Limagne. (2022) Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. OncoImmunology 11:1.
Read now
Read now
Yusuke Nagata, Shun Yamamoto & Ken Kato. (2022) Immune checkpoint inhibitors in esophageal cancer: Clinical development and perspectives. Human Vaccines & Immunotherapeutics 18:6.
Read now
Read now
Fateme Sheida, Sepideh Razi, Mahsa Keshavarz-Fathi & Nima Rezaei. (2022) The role of myeloid-derived suppressor cells in lung cancer and targeted immunotherapies. Expert Review of Anticancer Therapy 22:1, pages 65-81.
Read now
Read now
Nikhil Shukla & Nasser Hanna. (2021) Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small Cell Lung Cancer. Lung Cancer: Targets and Therapy 12, pages 51-60.
Read now
Read now
Glenn F. Van Wigcheren, Nienke De Haas, Tom A. Mulder, Sophie K. Horrevorts, Martine Bloemendal, Simone Hins-Debree, Yumeng Mao, Rolf Kiessling, Carla M.L. van Herpen, Georgina Flórez-Grau, Stanleyson V. Hato & I. Jolanda M. De Vries. (2021) Cisplatin inhibits frequency and suppressive activity of monocytic myeloid-derived suppressor cells in cancer patients. OncoImmunology 10:1.
Read now
Read now
Frank Weinberg & Shirish Gadgeel. (2019) Combination pembrolizumab plus chemotherapy: a new standard of care for patients with advanced non-small-cell lung cancer. Lung Cancer: Targets and Therapy 10, pages 47-56.
Read now
Read now
Hazem E. El-Osta, Frank E. Mott, Bryan M. Burt, Daniel Y. Wang & Anita L. Sabichi. (2019) Predictors of benefits from frontline chemoimmunotherapy in stage IV non-small-cell lung cancer: a meta-analysis. OncoImmunology 8:12.
Read now
Read now
Wayne J. Aston, Danika E. Hope, Alistair M. Cook, Louis Boon, Ian Dick, Anna K. Nowak, Richard A. Lake & W. Joost Lesterhuis. (2019) Dexamethasone differentially depletes tumour and peripheral blood lymphocytes and can impact the efficacy of chemotherapy/checkpoint blockade combination treatment. OncoImmunology 8:11.
Read now
Read now
Antonio Rossi. (2019) New options for combination therapy for advanced non-squamous NSCLC. Expert Review of Respiratory Medicine 13:11, pages 1095-1107.
Read now
Read now
Danilo Rocco, Luigi Della Gravara, Ciro Battiloro & Cesare Gridelli. (2019) The role of combination chemo-immunotherapy in advanced non-small cell lung cancer. Expert Review of Anticancer Therapy 19:7, pages 561-568.
Read now
Read now
Nikolaos F Pistamaltzian, Vassilis Georgoulias & Athanasios Kotsakis. (2019) The role of immune checkpoint inhibitors in advanced non-small cell lung cancer. Expert Review of Respiratory Medicine 13:5, pages 435-447.
Read now
Read now
Articles from other publishers (71)
Tao Jiang, Qiqi Jin, Jiahao Wang, Fengying Wu, Jian Chen, Gongyan Chen, Yunchao Huang, Jianhua Chen, Ying Cheng, QiMing Wang, Yueyin Pan, Jianying Zhou, Jianhua Shi, Xingxiang Xu, LiZhu Lin, Wei Zhang, Yiping Zhang, Yunpeng Liu, Yong Fang, Jifeng Feng, Zhehai Wang, Sheng Hu, Jian Fang, Yongqian Shu, Jiuwei Cui, Yi Hu, Wenxiu Yao, Xingya Li, Xiaoyan Lin, Rui Wang, Yongsheng Wang, Wei Shi, Gaohua Feng, Jun Ni, Beibei Mao, Dandan Ren, Huaibo Sun, Henghui Zhang, Luonan Chen, Caicun Zhou & Shengxiang Ren. (2023) HLA-I Evolutionary Divergence Confers Response to PD-1 Blockade plus Chemotherapy in Untreated Advanced Non–Small Cell Lung Cancer. Clinical Cancer Research 29:23, pages 4830-4843.
Crossref
Crossref
Jhon Jairo Calderon, Karol Prieto, Paola Lasso, Susana Fiorentino & Alfonso Barreto. (2023) Modulation of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment by Natural Products. Archivum Immunologiae et Therapiae Experimentalis 71:1.
Crossref
Crossref
Francisco Cezar Aquino de Moraes, Eric Pasqualotto, Lucca Moreira Lopes, Maria Eduarda Cavalcanti Souza, Anna Luíza Soares de Oliveira Rodrigues, Artur Menegaz de Almeida, Carlos Stecca, Marianne Rodrigues Fernandes & Ney Pereira Carneiro dos Santos. (2023) PD-1/PD-L1 inhibitors plus carboplatin and paclitaxel compared with carboplatin and paclitaxel in primary advanced or recurrent endometrial cancer: a systematic review and meta-analysis of randomized clinical trials. BMC Cancer 23:1.
Crossref
Crossref
Rachel S Goodman, Seungyeon Jung, Jessica Quintos & Douglas B Johnson. (2023) Therapeutic Responses to Combination Nivolumab and Temozolomide as Salvage Therapy for Metastatic Melanoma: A Case Series. The Oncologist 28:9, pages e839-e842.
Crossref
Crossref
Jeroen van Dorp & Michiel S. van der Heijden. (2023) The bladder cancer immune micro-environment in the context of response to immune checkpoint inhibition. Frontiers in Immunology 14.
Crossref
Crossref
Chi Chun Wong & Jun Yu. (2023) Gut microbiota in colorectal cancer development and therapy. Nature Reviews Clinical Oncology 20:7, pages 429-452.
Crossref
Crossref
Ryan D Gentzler, Nisha A Mohindra, Shadia I Jalal, Karen L Reckamp, Richard D Hall, Nasser H Hanna, Young Kwang Chae, Marianna Koczywas, Irene B Helenowski & Jyoti D Patel. (2023)
Phase I/II Trial of Carboplatin,
Nab
-paclitaxel, and Pembrolizumab for Advanced Non–Small Cell Lung Cancer: Hoosier Cancer Research Network LUN13-175
. The Oncologist.
Crossref
Crossref
Ramez N. EskanderMichael W. SillLindsey BeffaRichard G. Moore, Joanie M. HopeFernanda B. MusaRobert MannelMark S. ShahinGuilherme H. CantuariaEugenia GirdaCara MathewsJuraj KavecanskyCharles A. LeathIIIIIILilian T. GienEmily M. HinchcliffShashikant B. LeleLisa M. LandrumFloor BackesRoisin E. O’CearbhaillTareq Al BaghdadiEmily K. HillPremal H. ThakerVeena S. JohnStephen WelchAmanda N. FaderMatthew A. PowellCarol Aghajanian. (2023) Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer. New England Journal of Medicine 388:23, pages 2159-2170.
Crossref
Crossref
Wenjie Liu, Gengwei Huo & Peng Chen. (2023) Clinical benefit of pembrolizumab in treatment of first line non-small cell lung cancer: a systematic review and meta-analysis of clinical characteristics. BMC Cancer 23:1.
Crossref
Crossref
Keitaro Shimozaki, Izuma Nakayama, Toru Hirota & Kensei Yamaguchi. (2023) Current Strategy to Treat Immunogenic Gastrointestinal Cancers: Perspectives for a New Era. Cells 12:7, pages 1049.
Crossref
Crossref
Satoshi Muto, Akio Enta, Yoshiyuki Maruya, Sho Inomata, Hikaru Yamaguchi, Hayato Mine, Hironori Takagi, Yuki Ozaki, Masayuki Watanabe, Takuya Inoue, Takumi Yamaura, Mitsuro Fukuhara, Naoyuki Okabe, Yuki Matsumura, Takeo Hasegawa, Jun Osugi, Mika Hoshino, Mitsunori Higuchi, Yutaka Shio, Kazuyuki Hamada & Hiroyuki Suzuki. (2023) Wnt/β-Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. Biomedicines 11:1, pages 190.
Crossref
Crossref
Gopi S. Mohan, Daniel J. Kats, Samantha D. Martin & Pietro Miozzo. 2023. Palliative Care in Hematologic Malignancies and Serious Blood Disorders. Palliative Care in Hematologic Malignancies and Serious Blood Disorders
55
67
.
Rongbin Qi, Yingying Yu, Mo Shen, Dongqing Lv & Susu He. (2022) Current status and challenges of immunotherapy in ALK rearranged NSCLC. Frontiers in Oncology 12.
Crossref
Crossref
S. Sumodhee, L. Guo, L. Bouhlel, A. Picard, J. Otto, A.O. Naghavi, Q. Richier, A. Lévy, P.-Y. Bondiau, M. Poudenx, T. Passeron, J.-P. Lacour, H. Montaudié & J. Doyen. (2022) Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. Cancer/Radiothérapie 26:8, pages 1045-1053.
Crossref
Crossref
Ryota Nakamura, Tadaaki Yamada, Kenji Morimoto, Akira Nakao, Yasuhiro Goto, Yuri Ogura, Takayuki Takeda, Chieko Takumi, Keisuke Onoi, Yusuke Chihara, Ryusuke Taniguchi, Takahiro Yamada, Osamu Hiranuma, Satomi Tanaka, Yoshie Morimoto, Masahiro Iwasaku, Shinsaku Tokuda, Yoshiko Kaneko, Junji Uchino & Koichi Takayama. (2021) Impact of maintenance therapy following induction immunochemotherapy for untreated advanced non-small cell lung cancer patients. Journal of Cancer Research and Clinical Oncology 148:11, pages 2985-2994.
Crossref
Crossref
Taro Teshima, Yukari Kobayashi, Taketo Kawai, Yoshihiro Kushihara, Koji Nagaoka, Jimpei Miyakawa, Yoshiyuki Akiyama, Yuta Yamada, Yusuke Sato, Daisuke Yamada, Nobuyuki Tanaka, Tatsuhiko Tsunoda, Haruki Kume & Kazuhiro Kakimi. (2022) Principal component analysis of early immune cell dynamics during pembrolizumab treatment of advanced urothelial carcinoma. Oncology Letters 24:2.
Crossref
Crossref
Mingfeng He, Taihao Zheng, Xiaoyue Zhang, Yuan Peng, Xuan Jiang, Yusheng Huang, Benxu Tan & Zhenzhou Yang. (2021) First-line treatment options for advanced non-small cell lung cancer patients with PD-L1 ≥ 50%: a systematic review and network meta-analysis. Cancer Immunology, Immunotherapy 71:6, pages 1345-1355.
Crossref
Crossref
Ru Li, Mousumi Beto Mukherjee & Jun Lin. (2022) Coordinated Regulation of Myeloid-Derived Suppressor Cells by Cytokines and Chemokines. Cancers 14:5, pages 1236.
Crossref
Crossref
Mona Khoury, Idan Cohen & Gil Bar-Sela. (2022) “The Two Sides of the Same Coin”—Medical Cannabis, Cannabinoids and Immunity: Pros and Cons Explained. Pharmaceutics 14:2, pages 389.
Crossref
Crossref
Rashi Sehgal, Navkiran Kaur, Gayatri Ramakrishna & Nirupma Trehanpati. (2022) Immune Surveillance by Myeloid-Derived Suppressor Cells in Liver Diseases. Digestive Diseases 40:3, pages 301-312.
Crossref
Crossref
Yang Hu & Mark E. Burkard. (2021) Classes of therapeutics to amplify the immune response. Breast Cancer Research and Treatment 191:2, pages 277-289.
Crossref
Crossref
Defne Bayik, Juyeun Lee & Justin D. Lathia. 2022. Interaction of Immune and Cancer Cells. Interaction of Immune and Cancer Cells
189
217
.
Jue Zhu, Lifeng Yan & Qiming Wang. (2021) Efficacy of PD-1/PD-L1 inhibitors in ovarian cancer: a single-arm meta-analysis. Journal of Ovarian Research 14:1.
Crossref
Crossref
Cameron J. Herting, Matthew R. Farren, Yan Tong, Ziyue Liu, Bert O’Neil, Tanios Bekaii-Saab, Anne Noonan, Christopher McQuinn, Thomas A. Mace, Walid Shaib, Christina Wu, Bassel F. El-Rayes, Safi Shahda & Gregory B. Lesinski. (2021) A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186. Cancer Immunology, Immunotherapy 70:11, pages 3337-3348.
Crossref
Crossref
Raquel Muñoz, Alessandra Girotti, Denise Hileeto & Francisco Javier Arias. (2021) Metronomic Anti-Cancer Therapy: A Multimodal Therapy Governed by the Tumor Microenvironment. Cancers 13:21, pages 5414.
Crossref
Crossref
Kai Li, Houhui Shi, Benxia Zhang, Xuejin Ou, Qizhi Ma, Yue Chen, Pei Shu, Dan Li & Yongsheng Wang. (2021) Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Signal Transduction and Targeted Therapy 6:1.
Crossref
Crossref
Yosuke Miyamoto, Toshiyuki Kozuki, Keisuke Aoe, Sae Wada, Daijiro Harada, Michihiro Yoshida, Jun Sakurai, Katsuyuki Hotta & Nobukazu Fujimoto. (2021) JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma. Journal for ImmunoTherapy of Cancer 9:10, pages e003288.
Crossref
Crossref
Jacob Stultz & Lawrence Fong. (2021) How to turn up the heat on the cold immune microenvironment of metastatic prostate cancer. Prostate Cancer and Prostatic Diseases 24:3, pages 697-717.
Crossref
Crossref
Maria I. Toki, Nikos Syrigos & Kostas Syrigos. (2020) Hyperprogressive disease: A distinct pattern of progression to immune checkpoint inhibitors. International Journal of Cancer 149:2, pages 277-286.
Crossref
Crossref
Houhui Shi, Kai Li, Yanghong Ni, Xiao Liang & Xia Zhao. (2021) Myeloid-Derived Suppressor Cells: Implications in the Resistance of Malignant Tumors to T Cell-Based Immunotherapy. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Miaomiao Gou, Yong Zhang, Tiee Liu, Haiyan Si, Zhikuan Wang, Huan Yan, Niansong Qian & Guanghai Dai. (2021) PD-1 Inhibitors Could Improve the Efficacy of Chemotherapy as First-Line Treatment in Biliary Tract Cancers: A Propensity Score Matching Based Analysis. Frontiers in Oncology 11.
Crossref
Crossref
Mithunah Krishnamoorthy, Lara Gerhardt & Saman Maleki Vareki. (2021) Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy. Cells 10:5, pages 1170.
Crossref
Crossref
Elham Safarzadeh, Ali Mohammadi, Behzad Mansoori, Pascal H. G. Duijf, Shahryar Hashemzadeh, Vahid Khaze, Tohid Kazemi, Afshin Derakhshani, Nicola Silvestris & Behzad Baradaran. (2021) STAT3 Silencing and TLR7/8 Pathway Activation Repolarize and Suppress Myeloid-Derived Suppressor Cells From Breast Cancer Patients. Frontiers in Immunology 11.
Crossref
Crossref
Ayushi Rai, Saba Noor, Syed Ishraque Ahmad, Mohamed F. Alajmi, Afzal Hussain, Hashim Abbas & Gulam Mustafa Hasan. (2021) Recent Advances and Implication of Bioengineered Nanomaterials in Cancer Theranostics. Medicina 57:2, pages 91.
Crossref
Crossref
Weiqiang Lu, Weiwei Yu, Jiacheng He, Wenjuan Liu, Junjie Yang, Xianhua Lin, Yuanjin Zhang, Xin Wang, Wenhao Jiang, Jian Luo, Qiansen Zhang, Huaiyu Yang, Shihong Peng, Zhengfang Yi, Shancheng Ren, Jing Chen, Stefan Siwko, Ruth Nussinov, Feixiong Cheng, Hankun Zhang & Mingyao Liu. (2020) Reprogramming immunosuppressive myeloid cells facilitates immunotherapy for colorectal cancer. EMBO Molecular Medicine 13:1.
Crossref
Crossref
Sara Gottlieb, Claire O’Grady, Ariel Gliksberg & Paul Kent. (2021) Early Experiences with Triple Immunochemotherapy in Adolescents and Young Adults with High-Risk Fibrolamellar Carcinoma. Oncology 99:5, pages 310-317.
Crossref
Crossref
Yuru Nie, Weiqing Lu, Daiyu Chen, Huilin Tu, Zhenling Guo, Xuan Zhou, Meifang Li, Sanfang Tu & Yuhua Li. (2020) Mechanisms underlying CD19-positive ALL relapse after anti-CD19 CAR T cell therapy and associated strategies. Biomarker Research 8:1.
Crossref
Crossref
Jonas Kuon, Adriane Hommertgen, Johannes Krisam, Felix Lasitschka, Albrecht Stenzinger, Miriam Blasi, Farastuk Bozorgmehr, Martin Maenz, Meinhard Kieser, Marc Schneider & Michael Thomas. (2020) Durvalumab in frail and elderly patients with stage four non-small cell lung cancer: Study protocol of the randomized phase II DURATION trial. Trials 21:1.
Crossref
Crossref
Mohsen Keshavarz, Mir Saeed Ebrahimzadeh, Seyed Mohammad Miri, Hassan Dianat-Moghadam, Seyedeh Sara Ghorbanhosseini, Seyed Reza Mohebbi, Hossein Keyvani & Amir Ghaemi. (2020) Oncolytic Newcastle disease virus delivered by Mesenchymal stem cells-engineered system enhances the therapeutic effects altering tumor microenvironment. Virology Journal 17:1.
Crossref
Crossref
Zhijie Xu, Shuangshuang Zeng, Zhicheng Gong & Yuanliang Yan. (2020) Exosome-based immunotherapy: a promising approach for cancer treatment. Molecular Cancer 19:1.
Crossref
Crossref
Muhammad Khan, Zhihong Zhao, Sumbal Arooj, Yuxiang Fu & Guixiang Liao. (2020) Soluble PD-1: Predictive, Prognostic, and Therapeutic Value for Cancer Immunotherapy. Frontiers in Immunology 11.
Crossref
Crossref
Defne Bayik, Adam J. Lauko, Gustavo A. Roversi, Emily Serbinowski, Lou-Anne Acevedo-Moreno, Christopher Lanigan, Mushfig Orujov, Alice Lo, Tyler J. Alban, Adam Kim, Daniel J. Silver, Laura E. Nagy, J. Mark Brown, Daniela S. Allende, Federico N. Aucejo & Justin D. Lathia. (2020) Hepatobiliary malignancies have distinct peripheral myeloid-derived suppressor cell signatures and tumor myeloid cell profiles. Scientific Reports 10:1.
Crossref
Crossref
Sohini Roy, Tarsheen K. Sethi, David Taylor, Young J. Kim & Douglas B. Johnson. (2020) Breakthrough concepts in immune‐oncology: Cancer vaccines at the bedside. Journal of Leukocyte Biology 108:4, pages 1455-1489.
Crossref
Crossref
Yi Qin, Lili Jiang, Min Yu, Yanying Li, Xiaojuan Zhou, Yongsheng Wang, Youling Gong, Feng Peng, Jiang Zhu, Yongmei Liu, Yong Xu, Lin Zhou, You Lu & Meijuan Huang. (2020) PD-L1 expression is a promising predictor of survival in patients with advanced lung adenocarcinoma undergoing pemetrexed maintenance therapy. Scientific Reports 10:1.
Crossref
Crossref
Fabio Gomes, Melisa Wong, Nicolò Matteo Luca Battisti, Tiana Kordbacheh, Mandy Kiderlen, Alastair Greystoke & Andrea Luciani. (2020) Immunotherapy in older patients with non-small cell lung cancer: Young International Society of Geriatric Oncology position paper. British Journal of Cancer 123:6, pages 874-884.
Crossref
Crossref
Izabela Sieminska & Jarek Baran. (2020) Myeloid-Derived Suppressor Cells in Colorectal Cancer. Frontiers in Immunology 11.
Crossref
Crossref
Defne Bayik, Yadi Zhou, Chihyun Park, Changjin Hong, Daniel Vail, Daniel J. Silver, Adam Lauko, Gustavo Roversi, Dionysios C. Watson, Alice Lo, Tyler J. Alban, Mary McGraw, Mia Sorensen, Matthew M. Grabowski, Balint Otvos, Michael A. Vogelbaum, Craig Horbinski, Bjarne Winther Kristensen, Ahmad M. Khalil, Tae Hyun Hwang, Manmeet S. Ahluwalia, Feixiong Cheng & Justin D. Lathia. (2020) Myeloid-Derived Suppressor Cell Subsets Drive Glioblastoma Growth in a Sex-Specific Manner. Cancer Discovery 10:8, pages 1210-1225.
Crossref
Crossref
Enrica Balza, Barbara Carnemolla, Paola Orecchia, Anna Rubartelli, Alessandro Poggi & Lorenzo Mortara. (2020) Tumor Vasculature Targeted TNFα Therapy: Reversion of Microenvironment Anergy and Enhancement of the Anti-tumor Efficiency. Current Medicinal Chemistry 27:25, pages 4233-4248.
Crossref
Crossref
Manisit Das, Jun Li, Michelle Bao & Leaf Huang. (2020) Nano-delivery of Gemcitabine Derivative as a Therapeutic Strategy in a Desmoplastic KRAS Mutant Pancreatic Cancer. The AAPS Journal 22:4.
Crossref
Crossref
William H. Gmeiner. (2020) Fluoropyrimidine Modulation of the Anti-Tumor Immune Response―Prospects for Improved Colorectal Cancer Treatment. Cancers 12:6, pages 1641.
Crossref
Crossref
Daniel Vargas P. de Almeida, Lawrence Fong, Matthew B. Rettig & Karen A. Autio. (2020) Immune Checkpoint Blockade for Prostate Cancer: Niche Role or Next Breakthrough?. American Society of Clinical Oncology Educational Book:40, pages e89-e106.
Crossref
Crossref
Hidetoshi Hayashi & Kazuhiko Nakagawa. (2019) Combination therapy with PD-1 or PD-L1 inhibitors for cancer. International Journal of Clinical Oncology 25:5, pages 818-830.
Crossref
Crossref
Linda Tran & Dan Theodorescu. (2020) Determinants of Resistance to Checkpoint Inhibitors. International Journal of Molecular Sciences 21:5, pages 1594.
Crossref
Crossref
Annabelle J. Anandappa, Catherine J. Wu & Patrick A. Ott. (2020) Directing Traffic: How to Effectively Drive T Cells into Tumors. Cancer Discovery 10:2, pages 185-197.
Crossref
Crossref
Sun Min Lim, Min Hee Hong & Hye Ryun Kim. (2020) Immunotherapy for Non-small Cell Lung Cancer: Current Landscape and Future Perspectives. Immune Network 20:1.
Crossref
Crossref
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Roberto Ferrara, Arsela Prelaj, Giulia Galli, Giuseppe Viscardi, Benedetta Trevian, Monica Ganzinelli, Nicoletta Zilembo, Filippo de Braud, Marina Chiara Garassino & Claudia Proto. (2020) Facing the First-line in Metastatic Non-small-cell Lung Cancer – Immunotherapy and Chemotherapy. European Oncology & Haematology 16:1, pages 39.
Crossref
Crossref
Karlo Perica, Kevin J. Curran & Jae H. Park. 2020. Chimeric Antigen Receptor T-Cell Therapies for Cancer. Chimeric Antigen Receptor T-Cell Therapies for Cancer
29
44
.
Pacôme Lecot, Matthieu Sarabi, Manuela Pereira Abrantes, Julie Mussard, Leo Koenderman, Christophe Caux, Nathalie Bendriss-Vermare & Marie-Cécile Michallet. (2019) Neutrophil Heterogeneity in Cancer: From Biology to Therapies. Frontiers in Immunology 10.
Crossref
Crossref
Ryul Kim, Bhumsuk Keam, Seokyung Hahn, Chan-Young Ock, Miso Kim, Tae Min Kim, Dong-Wan Kim & Dae Seog Heo. (2019) First-line Pembrolizumab Versus Pembrolizumab Plus Chemotherapy Versus Chemotherapy Alone in Non–small-cell Lung Cancer: A Systematic Review and Network Meta-analysis. Clinical Lung Cancer 20:5, pages 331-338.e4.
Crossref
Crossref
J. Corral, M. Majem, D. Rodríguez-Abreu, E. Carcereny, Á. A. Cortes, M. Llorente, J. M. López Picazo, Y. García, M. Domine & M P. López Criado. (2019) Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program. Clinical and Translational Oncology 21:9, pages 1270-1279.
Crossref
Crossref
Danyang Sun, Junxun Ma, Jinliang Wang, Chun Han, Yuanyu Qian, Guangying Chen, Xiaoyan Li, Juan Zhang, Pengfei Cui, Wushuang Du, Zhaozhen Wu, Shixue Chen, Xuan Zheng, Zhichao Yue, Jia Song, Chan Gao, Xiaochen Zhao, Shangli Cai & Yi Hu. (2019) Anti-PD-1 therapy combined with chemotherapy in patients with advanced biliary tract cancer. Cancer Immunology, Immunotherapy 68:9, pages 1527-1535.
Crossref
Crossref
Chongkai Wang, Prakash Kulkarni & Ravi Salgia. (2019) Combined Checkpoint Inhibition and Chemotherapy: New Era of 1st-Line Treatment for Non-Small-Cell Lung Cancer. Molecular Therapy - Oncolytics 13, pages 1-6.
Crossref
Crossref
C. Proto, R. Ferrara, D. Signorelli, G. Lo Russo, G. Galli, M. Imbimbo, A. Prelaj, N. Zilembo, M. Ganzinelli, L.M. Pallavicini, I. De Simone, M.P. Colombo, A. Sica, V. Torri & M.C. Garassino. (2019) Choosing wisely first line immunotherapy in non-small cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treatment Reviews 75, pages 39-51.
Crossref
Crossref
Seung Hyeun Lee. (2019) Chemotherapy for Lung Cancer in the Era of Personalized Medicine. Tuberculosis and Respiratory Diseases 82:3, pages 179.
Crossref
Crossref
Maxime Chénard-Poirier & Elizabeth C. Smyth. (2019) Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer. Drugs 79:1, pages 1-10.
Crossref
Crossref
Na‐Rae Kim & Yeon‐Jeong Kim. (2018) Oxaliplatin regulates myeloid‐derived suppressor cell‐mediated immunosuppression via downregulation of nuclear factor‐κB signaling. Cancer Medicine 8:1, pages 276-288.
Crossref
Crossref
Xiaolei Li, Changshun Shao, Yufang Shi & Weidong Han. (2018) Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. Journal of Hematology & Oncology 11:1.
Crossref
Crossref
Yilin Zhao, Qi Shao, Haitao Zhu, Haiyuan Xu, Wei Long, Bin Yu, Lining Zhou, Huaxi Xu, Yan Wu & Zhaoliang Su. (2018) Resveratrol ameliorates Lewis lung carcinoma‐bearing mice development, decreases granulocytic myeloid‐derived suppressor cell accumulation and impairs its suppressive ability. Cancer Science 109:9, pages 2677-2686.
Crossref
Crossref
Leena GandhiDelvys Rodríguez-AbreuShirish GadgeelEmilio EstebanEnriqueta FelipFlávia De AngelisManuel DominePhilip ClinganMaximilian J. HochmairSteven F. PowellSusanna Y.-S. ChengHelge G. BischoffNir PeledFrancesco GrossiRoss R. JennensMartin ReckRina HuiEdward B. GaronMichael BoyerBelén Rubio-ViqueiraSilvia NovelloTakayasu KurataJhanelle E. GrayJohn VidaZiwen WeiJing YangHarry RaftopoulosM. Catherine PietanzaMarina C. Garassino. (2018) Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. New England Journal of Medicine 378:22, pages 2078-2092.
Crossref
Crossref
Nicola R. Hardwick, Paul Frankel, Christopher Ruel, Julie Kilpatrick, Weimin Tsai, Ferdynand Kos, Teodora Kaltcheva, Lucille Leong, Robert Morgan, Vincent Chung, Raechelle Tinsley, Melissa Eng, Sharon Wilczynski, Joshua D.I. Ellenhorn, Don J. Diamond & Mihaela Cristea. (2018) p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy. Clinical Cancer Research 24:6, pages 1315-1325.
Crossref
Crossref
Alessandro Poggi, Serena Varesano & Maria Raffaella Zocchi. (2018) How to Hit Mesenchymal Stromal Cells and Make the Tumor Microenvironment Immunostimulant Rather Than Immunosuppressive. Frontiers in Immunology 9.
Crossref
Crossref